187 related articles for article (PubMed ID: 29189632)
21. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
[TBL] [Abstract][Full Text] [Related]
22. Role of 18F-FDG-PET/CT in the management of Burkitt lymphoma.
Carrillo-Cruz E; Marín-Oyaga VA; Solé Rodríguez M; Borrego-Dorado I; de la Cruz Vicente F; Quiroga Cantero E; Manzanares Pérez M; Capote FJ; Ramírez Sánchez MJ; Espigado Tocino I; Pérez-Vega H; Vázquez-Albertino R; Pérez-Simón JA
Eur J Haematol; 2015 Jan; 94(1):23-30. PubMed ID: 24520874
[TBL] [Abstract][Full Text] [Related]
23. Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.
Caobelli F; Alongi P; Evangelista L; Picchio M; Saladini G; Rensi M; Geatti O; Castello A; Laghai I; Popescu CE; Dolci C; Crivellaro C; Seghezzi S; Kirienko M; De Biasi V; Cocciolillo F; Quartuccio N;
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):404-13. PubMed ID: 26381775
[TBL] [Abstract][Full Text] [Related]
24. Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German Posttransplant Lymphoproliferative Disorder Registry.
Zimmermann H; Oschlies I; Fink S; Pott C; Neumayer HH; Lehmkuhl H; Hauser IA; Dreyling M; Kneba M; Gärtner B; Anagnostopoulos I; Riess H; Klapper W; Trappe RU
Transplantation; 2012 Mar; 93(5):543-50. PubMed ID: 22234349
[TBL] [Abstract][Full Text] [Related]
25. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
26. PET-CT as an effective imaging modality in the staging and follow-up of post-transplant lymphoproliferative disorder following solid organ transplantation.
Noraini AR; Gay E; Ferrara C; Ravelli E; Mancini V; Morra E; Muti P; Tahir A; Abdul Jalil N; Rossetti C
Singapore Med J; 2009 Dec; 50(12):1189-95. PubMed ID: 20087557
[TBL] [Abstract][Full Text] [Related]
27. Value of [18F]fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: the end of a dilemma?
Janikova A; Bolcak K; Pavlik T; Mayer J; Kral Z
Clin Lymphoma Myeloma; 2008 Oct; 8(5):287-93. PubMed ID: 18854283
[TBL] [Abstract][Full Text] [Related]
28. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
Berthet L; Cochet A; Kanoun S; Berriolo-Riedinger A; Humbert O; Toubeau M; Dygai-Cochet I; Legouge C; Casasnovas O; Brunotte F
J Nucl Med; 2013 Aug; 54(8):1244-50. PubMed ID: 23674577
[TBL] [Abstract][Full Text] [Related]
29. Preliminary experience on the use of PET/CT in the management of pediatric post-transplant lymphoproliferative disorder.
Guerra-García P; Hirsch S; Levine DS; Taj MM
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28612477
[TBL] [Abstract][Full Text] [Related]
30. Role of 18F-FDG-PET/CT in the management of marginal zone B cell lymphoma.
Carrillo-Cruz E; Marín-Oyaga VA; de la Cruz Vicente F; Borrego-Dorado I; Ruiz Mercado M; Acevedo Báñez I; Solé Rodríguez M; Fernández López R; Pérez Vega H; Calderón-Cabrera C; Espigado Tocino I; Pérez-Simón JA; Vázquez-Albertino R
Hematol Oncol; 2015 Dec; 33(4):151-8. PubMed ID: 25407794
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
Spaepen K; Stroobants S; Dupont P; Van Steenweghen S; Thomas J; Vandenberghe P; Vanuytsel L; Bormans G; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
J Clin Oncol; 2001 Jan; 19(2):414-9. PubMed ID: 11208833
[TBL] [Abstract][Full Text] [Related]
32. Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.
Trappe RU; Dierickx D; Zimmermann H; Morschhauser F; Mollee P; Zaucha JM; Dreyling MH; Dührsen U; Reinke P; Verhoef G; Subklewe M; Hüttmann A; Tousseyn T; Salles G; Kliem V; Hauser IA; Tarella C; Van Den Neste E; Gheysens O; Anagnostopoulos I; Leblond V; Riess H; Choquet S
J Clin Oncol; 2017 Feb; 35(5):536-543. PubMed ID: 27992268
[TBL] [Abstract][Full Text] [Related]
33. Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation.
Bakker NA; van Imhoff GW; Verschuuren EA; van Son WJ
Transpl Int; 2007 Mar; 20(3):207-18. PubMed ID: 17291214
[TBL] [Abstract][Full Text] [Related]
34. Midtreatment ¹⁸F-FDG PET/CT Scan for Early Response Assessment of SMILE Therapy in Natural Killer/T-Cell Lymphoma: A Prospective Study from a Single Center.
Khong PL; Huang B; Lee EY; Chan WK; Kwong YL
J Nucl Med; 2014 Jun; 55(6):911-6. PubMed ID: 24819420
[TBL] [Abstract][Full Text] [Related]
35. Absence of infective endocarditis relapse when end-of-treatment fluorodeoxyglucose positron emission tomography/computed tomography is negative.
Régis C; Thy M; Mahida B; Deconinck L; Tubiana S; Iung B; Duval X; Rouzet F
Eur Heart J Cardiovasc Imaging; 2023 Oct; 24(11):1480-1488. PubMed ID: 37307564
[TBL] [Abstract][Full Text] [Related]
36. The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas.
Schrepfer T; Haerle SK; Strobel K; Schaefer N; Hälg RA; Huber GF
Laryngoscope; 2010 May; 120(5):937-44. PubMed ID: 20422687
[TBL] [Abstract][Full Text] [Related]
37. Multicenter Comparison of Contrast-Enhanced FDG PET/CT and 64-Slice Multi-Detector-Row CT for Initial Staging and Response Evaluation at the End of Treatment in Patients With Lymphoma.
Gómez León N; Delgado-Bolton RC; Del Campo Del Val L; Cabezas B; Arranz R; García M; Cannata J; González Ortega S; Pérez Sáez MÁ; López-Botet B; Rodríguez-Vigil B; Mateo M; Colletti PM; Rubello D; Carreras JL
Clin Nucl Med; 2017 Aug; 42(8):595-602. PubMed ID: 28604477
[TBL] [Abstract][Full Text] [Related]
38. FDG-PET/CT in abdominal post-transplant lymphoproliferative disease.
Metser U; Lo G
Br J Radiol; 2016; 89(1057):20150844. PubMed ID: 26544161
[TBL] [Abstract][Full Text] [Related]
39. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF
Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
[TBL] [Abstract][Full Text] [Related]
40. Performance of advanced imaging modalities at diagnosis and treatment response evaluation of patients with post-transplant lymphoproliferative disorder: A systematic review and meta-analysis.
Montes de Jesus FM; Kwee TC; Nijland M; Kahle XU; Huls G; Dierckx RAJO; van Meerten T; Gheysens O; Dierickx D; Vergote V; Noordzij W; Glaudemans AWJM
Crit Rev Oncol Hematol; 2018 Dec; 132():27-38. PubMed ID: 30447925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]